Keyword Analysis & Research: tagrisso

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
tagrisso1.3717343338

Keyword Research: People who searched tagrisso also searched

Keyword CPC PCC Volume Score
tagrisso0.30.269091
tagrisso medication1.530.451581
tagrisso side effects0.410.44703100
tagrisso 80 mg1.470.2690214
tagrisso cost1.980.1508527
tagrisso package insert0.920.8570149
tagrisso chemotherapy1.950.3699312
tagrisso lung cancer0.370.9565176
tagrisso pi1.160.664579
tagrisso life expectancy1.20.665253
tagrisso copay card1.920.4960016
tagrisso website0.180.31689100
tagrisso package insert 20230.750.772597
tagrisso cancer drug0.170.66284
tagrisso package insert fda1.220.28602
tagrisso package insert pdf1.640.5373437
tagrisso smpc1.80.216976

Search Results related to tagrisso on Search Engine

  • Treatment for Certain Types of EGFR+ NSCLC | TAGRISSO® …

    tagrisso.com

    https://www.tagrisso.com/

    WEBEGFR+ is Epidermal growth factor receptor mutation-positive; NSCLC is non-small cell lung cancer. Learn about TAGRISSO® (osimertinib), a targeted treatment option for people with certain types of EGFR+ non-small cell lung cancer (NSCLC). Talk to your doctor to see if TAGRISSO is right for you.

    DA: 99 PA: 55 MOZ Rank: 68

  • Tagrisso: Uses, Dosage, Side Effects & Warnings - Drugs.com

    drugs.com

    https://www.drugs.com/tagrisso.html

    WEBFeb 22, 2024 · Tagrisso (osimertinib) is an oral kinase inhibitor that may be used to treat adults with non-small cell lung cancer (NSCLC) whose tumors have certain abnormal epidermal growth factor receptor (EGFR) gene (s). It …

    DA: 11 PA: 23 MOZ Rank: 62

  • Tagrisso: Side Effects, Cost, Uses, and More - Healthline

    healthline.com

    https://www.healthline.com/health/drugs/tagrisso

    WEBApr 24, 2022 · Tagrisso is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. Specifically, Tagrisso is used to treat NSCLC that’s EGFR-positive (EGFR+).

    DA: 45 PA: 83 MOZ Rank: 31

  • Osimertinib - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/Osimertinib

    WEBOsimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

    DA: 14 PA: 98 MOZ Rank: 51

  • Tagrisso oral: Uses, Side Effects, Interactions, Pictures ... - WebMD

    webmd.com

    https://www.webmd.com/drugs/2/drug-170434/tagrisso-oral/details

    WEBTagrisso - Uses, Side Effects, and More. Generic Name: osimertinib. This medication is used to treat lung cancer. Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by...

    DA: 44 PA: 14 MOZ Rank: 78

  • Tagrisso: Side effects, cost, uses, interactions, dosage, and more

    medicalnewstoday.com

    https://www.medicalnewstoday.com/articles/drugs-tagrisso

    WEBJan 26, 2022 · What is Tagrisso? Tagrisso is a brand-name prescription medication. It’s FDA-approved to treat certain types of non-small cell lung cancer (NSCLC) in adults. Specifically, Tagrisso is approved...

    DA: 47 PA: 18 MOZ Rank: 15

  • TAGRISSO® achieved unprecedented survival in early-stage …

    astrazeneca-us.com

    https://www.astrazeneca-us.com/media/press-releases/2023/tagrisso-achieved-unprecedented-survival-in-early-stage-egfr-mutated-lung-cancer-with-88-of-patients-alive-at-five-years-in-adaura-phase-iii-trial-06042023.html

    WEBJun 4, 2023 · TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial. PUBLISHED 4 June 2023. Treatment with adjuvant TAGRISSO reduced the risk of …

    DA: 68 PA: 41 MOZ Rank: 90

  • FDA Approves First Adjuvant Therapy for Most Common Type of …

    fda.gov

    https://www.fda.gov/news-events/press-announcements/fda-approves-first-adjuvant-therapy-most-common-type-lung-cancer

    WEBDecember 18, 2020. Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a...

    DA: 63 PA: 33 MOZ Rank: 33

  • Osimertinib Improves Survival in Lung Cancer - NCI

    cancer.gov

    https://www.cancer.gov/news-events/cancer-currents-blog/2023/osimertinib-lung-cancer-adaura

    WEBJul 5, 2023 · Home. News & Events. Cancer Currents Blog. Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism. Subscribe. July 5, 2023 , by Carmen Phillips. Results from the ADAURA trial are expected to have an impact on the treatment of early-stage lung cancer, including people with stage IB disease. Credit: © Terese Winslow.

    DA: 68 PA: 8 MOZ Rank: 32

  • Tagrisso | European Medicines Agency

    europa.eu

    https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso

    WEBFeb 17, 2016 · Overview. Tagrisso is a medicine for treating a lung cancer called non-small cell lung cancer (NSCLC). It is used on its own in patients whose cancer cells have certain mutations (changes) in a gene for a. protein called EGFR. • In patients whose cancer cells have genetic changes known as Ex19del or L858R and whose.

    DA: 66 PA: 41 MOZ Rank: 15